Hong Kong Med J 2014 Aug;20(4):325–30 | Epub 20 June 2014
MEDICAL PRACTICE CME
Immunotherapy for peanut allergy
TH Lee, ScD, FRCP1; June Chan, BSc, MSc1; Vivian WY Lau, BSc, MSc1; WL Lee, BNurs, MNurs1; PC Lau, BNurs1; MH Lo, BSc, MSc2
1 Allergy Centre, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong
2 Department of Pathology, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong
Corresponding author: Dr TH Lee (email@example.com)Full paper in PDF
Peanut allergy is one of the commonest food hypersensitivities causing fatal or near-fatal reactions. There is, currently, no preventive treatment and the incidence of severe allergic reactions during peanut desensitisation has limited its clinical use. Anti–immunoglobulin E therapy has been shown to be effective in preventing peanut-induced reactions but it does not result in long-term tolerance. Two important advances have recently been reported. One involves gradual oral introduction of peanut protein to desensitise, whereas the other approach uses a combination of anti–immunoglobulin E and oral peanut immunotherapy. Both approaches could offer a way to desensitise with a far greater margin of safety than has, hitherto, been reported. This article provides an overview of the literature on peanut immunotherapy and describes the experience in a small group of children in Hong Kong who were treated successfully using anti–immunoglobulin E combined with oral peanut desensitisation.
Peanut allergy is the commonest food hypersensitivity causing fatal or near-fatal reactions in the western world.1 There has been a longstanding but erroneous belief that peanut allergy is less prevalent in Hong Kong compared with other countries. Two studies have estimated the prevalence of allergic reactions after eating peanuts in children living in Hong Kong to be 0.6% and 0.3%, respectively,2 3 which is similar to pooled international data. Strikingly, 700/100 000 of the population in Hong Kong aged 14 years or younger is estimated to have a risk of anaphylaxis3 and peanut is a leading causative food allergen alongside shellfish, egg, milk, beef, and tree nuts.2 3
The current medical management of peanut allergy is to encourage strict avoidance of peanuts and to use self-administered adrenaline for anaphylaxis due to inadvertent ingestion. Dietary restrictions are not only difficult but also stressful for the patient and families. Reactions from accidental exposure are common and annual incidence rates range from 3% to 50%.4 Furthermore, adrenaline is not always accessible for emergency use. It is, therefore, essential to discover ways to prevent allergic reactions caused by peanut exposure. While herbal remedies may show some promise,5 6 most of the previous studies have tested the efficacy and safety of desensitisation.
Food desensitisation means an increase in threshold of food antigen causing allergic symptoms and depends on the regular (usually daily) consumption of the food. When dosing is interrupted, any protective effect may be lost or attenuated. Mechanisms for desensitisation include decreased allergen-specific immunoglobulin E (IgE), increased allergen-specific IgG4, and reduced responsiveness of mast cells and basophils. In established oral tolerance, the food can be eaten without allergic problems even when regular dosing ceases. Mechanisms responsible for oral tolerance likely involve recruitment of regulatory T cells with a shift away from the pro-allergic T helper cell subtype 2 (TH2) phenotype. There is scant information on long-term outcomes and tolerance following oral immunotherapy (OIT) in food allergy.
Previous immunotherapy trials
There are no immunotherapy regimens in routine use for peanut allergy. Most (but not all) peanut immunotherapy protocols involve an initial escalation phase (range, 0-7 days) of orally administered peanut, or a pre-immunotherapy oral peanut challenge, to determine the starting dose for OIT. This is followed by administration of further build-up doses (range, 0-22 months) and then maintenance doses (range, 1-36 months).
The maximum maintenance doses are between 300 mg and 4000 mg peanut protein. While some studies have shown encouraging results,7 8 9 10 11 12 the risk of severe reactions during peanut OIT is of concern.
Clark et al7 reported that four children underwent successful peanut OIT starting from 5 mg peanut protein to reach a maintenance dose of 800 mg peanut protein after 12 biweekly increments. During the final open challenge, all four subjects could ingest between 2380 mg and 2760 mg peanut protein reflecting an increase in dose threshold of at least 48-478 fold. Hofmann et al8 showed that 20 of 28 subjects were able to complete peanut OIT to reach a daily maintenance dose of 300 mg. Jones et al9 showed that 27 of 29 subjects with peanut allergy could be desensitised. Before OIT, they were developing reactions to eating less than 50 mg peanut protein but after 4 to 22 months of daily maintenance dosing with 300 mg, they were able to ingest 3900 mg. Similarly, Blumchen et al10 reported successfully desensitising 14 of 23 subjects with OIT to reach a maintenance dose of 500 mg peanut. Anagnostou et al11 reported successful desensitisation in 19 of 22 patients. Thirty weeks into the maintenance phase of OIT and ingesting 800 mg peanut protein daily, the subjects could eat a mean dose of peanut that was 1000-fold greater than baseline. Varshney et al12 published the first double-blind placebo-controlled study of peanut OIT and showed that 16 of 19 subjects were able to consume 4000 mg after 12 months of OIT.
In these reports, while allergic symptoms were uncommon during maintenance dosing (2.1%-3.7% of doses), they were very common during the initial escalation phase (47%-100% of patients) and the build-up phase (1.2%-46% of doses).7 8 9 10 11 12 Up to 10.5% of the subjects required adrenaline treatment on the initial escalation day. The dropout rate was high (4.5%-10.7%) due to the severity of allergic complications. These problems have greatly restricted the use of oral peanut desensitisation.
Use of sublingual immunotherapy (SLIT) may hold promise but there is limited experience with this form of desensitisation in peanut allergy. Kim et al13 successfully desensitised 18 children with peanut allergy using SLIT over 12 months. As assessed by double-blind placebo-controlled food challenges, the treatment group was able to ingest 20 times more peanut protein compared with the placebo group (median, 1710 vs 85 mg peanut protein). In 2013, Fleischer et al14 showed that after 44 weeks of SLIT, 14 out of 20 peanut-allergic subjects showed increased ability to ingest peanut protein from 3.5 mg to 496 mg; and after 68 weeks of SLIT, the increase was twice as high at 996 mg. Allergic symptoms developing during SLIT were reported with 11.5% of peanut doses and 8.6% of placebo doses. Of the 4182 active peanut doses, only 0.26% of the doses taken at home required antihistamine treatment and 0.02% required use of salbutamol. Thus, with the limited data available, SLIT appeared to have fewer allergic side-effects than OIT.
Anti-IgE administration has the potential to prevent peanut allergy,15 16 as it reduces free-circulating IgE levels and inhibits expression of the high-affinity IgE receptor on mast cells and other immune cells.17 18 19 20 Leung et al15 showed that 450 mg of a humanised IgG1 monoclonal antibody against IgE significantly increased the threshold of sensitivity to peanut on oral food challenge from approximately half a peanut to almost nine peanuts. Similarly, Sampson et al16 have suggested that the anti-IgE monoclonal antibody omalizumab (Xolair; Novartis, Basel, Switzerland), which is approved in Hong Kong and in many other countries for treating severe asthma, could increase the tolerability to peanut. Unfortunately, this latter study was terminated early because of two severe anaphylactic reactions after oral peanut challenge during the recruitment phase.
These results are encouraging but Xolair has to be administered by subcutaneous injection. As the dose and frequency of administration are determined by total serum IgE and body weight, it is suited optimally for only those within 20% of the ideal body weight. Furthermore, the drug is expensive and peanut allergy relapses soon after anti-IgE is discontinued; thus, it cannot induce long-term tolerance, which may likely require specific allergen immunotherapy.
There have been some recent advances in peanut OIT that look promising. Anagnostou et al21 conducted a randomised controlled cross-over trial comparing OIT using peanut flour with peanut avoidance. They reported successful OIT in 62% of a group of children aged 7 to 16 years with peanut allergy. There was an initial updosing schedule of biweekly increments up to a maximum oral intake of 800 mg peanut protein/day. This was followed by a maintenance period when the highest dose that could be safely eaten was taken daily for 26 weeks. By this time, 91% could ingest 800 mg peanut protein daily versus none in the control group, and 54% had no reactions to a 1400 mg peanut challenge. Side-effects were reported in 20% of subjects but they were mostly mild consisting mainly of gastro-intestinal symptoms and oral pruritus. The median peanut threshold dose had increased by 25.5-fold.
In light of the biological activities of Xolair, it was logical to combine it with peanut OIT to test whether the drug can facilitate allergen-specific desensitisation by reducing incidence of side-effects. A period of pretreatment with anti-IgE has already been reported to decrease acute allergic reactions developing during rush immunotherapy for ragweed-induced seasonal rhinitis and milk allergy.22 23
Schneider et al24 treated 13 children with a brief course of Xolair over 20 weeks. At 12 weeks of Xolair administration, OIT was started. On the first day of OIT, 11 desensitising doses of peanut flour were given over 6 hours (rush OIT). This was followed by a slower escalation phase of peanut allergen doses at weekly intervals for 7 to 12 weeks until the subjects were receiving 4000 mg of peanut flour (equivalent to about 9-10 peanuts) daily at which time Xolair was discontinued. The children then continued to ingest 4000 mg peanut flour daily during maintenance phase. On this regimen, the subjects were able to ingest 160 to 400 times the dose that could be eaten before OIT. The rapidity with which the patients reached 4000 mg was notable and this was achieved with only about 2% of the peanut doses associated with mild allergic reactions. The initial rush desensitisation allowed the patients to ingest a cumulative dose of 992 mg peanut flour (about 2 peanuts) after only 24 hours of OIT. This would have removed the patient very rapidly from risk of anaphylaxis caused by accidental exposure.
Schneider et al’s report24 is very similar to our experience in Hong Kong. We have completed the first phase of a small pilot desensitisation study in four children with mild-to-moderately severe peanut allergy in which Xolair and peanut OIT were combined. The inclusion criteria for the study were volunteers aged 8 years or older with a history of peanut allergy manifested by any of the following: urticaria, angioedema, asthma, gastro-intestinal symptoms, or anaphylaxis within 60 minutes of ingestion; a serum total IgE between 30 and 1500 IU/mL; a positive double-blind placebo-controlled oral peanut challenge; good general health; within 20% of ideal body weight; a positive skin prick test (at least 3 x 3 mm wheal greater than diluent control); a positive serum-specific IgE to peanut as measured by radioallergosorbent test (RAST); and no prior exposure to monoclonal antibodies. Asthma must have been stable with a forced expiratory volume in 1 second of at least 80% predicted value. Systemic glucocorticoids, beta blockers, and angiotensin-converting enzyme inhibitors were prohibited before screening and throughout the study. Aspirin, antihistamines, and antidepressants were not permitted for 3 days, 1 week, and 2 weeks, respectively, before skin testing or oral food challenge. If patients had poorly controlled asthma and/or atopic dermatitis, or inability to discontinue antihistamines or other medications for skin testing and oral challenges, they were excluded. They were also deemed ineligible if it seemed unlikely that they would be able to comply with the study protocol for any reason. The subjects were recruited from patients attending the Allergy Centre at the Hong Kong Sanatorium and Hospital. The study was approved by the Hospital Research Ethics Committee; both written informed consent from the children’s parents and the children’s informed verbal assent were obtained. The inclusion and exclusion criteria for the previous trials cited in this review are included in Table 1 7 8 9 10 11 12 13 14 21 24 for comparison.
Table 1. Indications and contra-indications for oral and sublingual immunotherapy in previous trials for peanut allergy
The children in our study had a history of peanut allergy manifested by urticaria, angioedema, asthma, sore mouth, and anaphylaxis within minutes of ingestion (Table 2). Their serum total IgE levels were raised and they had a positive skin prick test and RAST to peanut. They were also positive for specific IgE to Ara h 2, a molecular component of peanut protein which, at high levels, is reported to identify a subgroup of subjects allergic to peanut with more severe symptoms, although this issue is considered debatable.25 Each child had a positive, double-blinded oral peanut challenge at recruitment confirming their clinical allergy.
Table 2. Characteristics, IgE, IgG4, FEV1, and peanut sensitivity (skin testing and oral challenge) before and following omalizumab (Xolair, Novartis) combined with oral peanut immunotherapy in four subjects
The study protocol had three stages. In stage 1, each subject received Xolair for 16 to 18 weeks. At 12 weeks of Xolair treatment, each subject had a graded oral peanut challenge to ensure that Xolair had increased the amount of peanut protein that could be ingested. If the challenge showed at least a two-step increase in the threshold dose of peanut provoking a reaction compared with baseline, OIT was started. If the increase in threshold was less than two-dose steps, the peanut challenge was repeated 4 weeks later to ensure that the threshold target had been met before OIT was initiated; if not, the subject was withdrawn. In stage 2, OIT had an escalation phase of peanut oral administration with updosing at biweekly intervals. In the most sensitive subjects, the doses could be: 0.5, 1, 2, 5, 12, 25, 50, 100, 200, 400, 800, 1200, 1600, and 2000 mg of peanut protein, given as defatted peanut flour with 50% peanut protein by weight. However, if subjects became less sensitised to peanut during Xolair treatment, as was the case in all our four subjects, the escalation phase might start in the mid-range of the dose range indicated above, thus, shortening the escalation phase considerably. The escalation phase was followed by maintenance phase when subjects continued to ingest the top dose of peanut (4000 mg peanut flour) for 36 months. Stage 3 was started when OIT ceased after 36 months and subsequent progress was monitored to assess whether long-term tolerance had been induced over the next 36 months (end of stage 3). Our study subjects are in stage 2 of the pilot study.
The Hong Kong protocol differed from Schneider et al’s24 in some respects. We treated the children with Xolair for 16 to 18 weeks and not 20 weeks. The Xolair treatment only overlapped the initial few weeks of OIT in the Hong Kong subjects whereas in Schneider’s protocol, Xolair was administered during the entire build-up phase of OIT. The serum elimination half-life of Xolair averaged about 26 days, so even when the injections were stopped, the drug effect would likely have persisted significantly longer. We did not have a rush OIT phase, preferring to updose more slowly at biweekly intervals to give a wider margin of safety. As a consequence, the duration of our escalation phase was slightly longer (14 weeks) compared with 7 to 12 weeks in the Schneider et al’s study.24 Despite these differences in protocol design, the results were very similar between the two studies.
One subject (subject 1) experienced mild abdominal cramps and mild oral itching when eating 4000 mg peanut flour (2000 mg peanut protein; equivalent to about 9 peanuts as each peanut contains about 240 mg peanut protein) as a single daily dose at home, but was able to ingest the dose when administered in two 2000 mg doses separated by at least 30 minutes. Compared with baseline, when subjects could only eat 2 to 12 mg peanut flour, at the end of the escalation phase on formal challenge under supervision, three subjects could eat a cumulative maximum dose of 9600 mg peanut flour (about 20 peanuts) [Table 2]. Subject 1 could eat a cumulative dose of 5600 mg (about 11 peanuts) but reacted at 9600 mg with mild abdominal cramps which resolved spontaneously. On the combination regimen, the children were, therefore, able to eat between 466- and 4800-fold more peanut protein than before they were desensitised. Subjects’ threshold skin prick test reactions to peanut extract had also increased (10-100 fold) [Table 2]. Thus, at the end of the escalation phase, all the children could ingest many more peanuts than would have been eaten inadvertently, and were protected from severe allergic reactions after accidental ingestion.
The clinical improvement was accompanied by an increase in each subject’s peanut-specific IgG4, suggesting mechanistic recruitment of the interleukin-10/Treg pathway and a shift away from the pro-allergic TH2 phenotype. It was noted that serum peanut-specific IgE increased in three out of the four children following Xolair and updosing of allergen, when concentrations might have been expected to decrease, as in other forms of allergen-specific desensitisation (Table 2). Interpretation of IgE measurements following Xolair administration is difficult because the drug complexes with free-circulating IgE resulting in an apparent increase in total IgE levels that may last for many weeks after treatment.26 Measurement of free-serum IgE would circumvent this problem but this is technically difficult to assay and was not performed in our laboratory. Instead, we used extinction skin prick tests as a surrogate marker of mast cell-bound peanut-specific IgE.
The incidence of side-effects during desensitisation in our limited experience was 0.2% of total number of peanut doses, which is much less than the incidence reported previously in the absence of Xolair cover7 8 9 10 11 12 and even less than the 2% reported recently.24
The results of recent studies taken together are encouraging and strongly suggest that there are several new strategies, including the use of anti-IgE with OIT, that could now allow desensitisation to peanut to be undertaken safely and, in one study, very rapidly. These approaches may have merit in the future for treating severe peanut allergy once protocols have been refined and results validated. However, these treatment regimens should always be used by experienced and appropriately trained clinicians, in an environment where facilities are available for emergency resuscitation in case a serious adverse event occurs. Whether the regimens can induce long-term tolerance will have to await review of progress when OIT ceases after 3 years.
The authors thank The Hong Kong Sanatorium and Hospital for support and to the study steering group (Dr YC Tsao, Dr Walton Li, Prof Raymond Liang, Prof Kar-nang Lai, Dr Edmond Ma, and Dr Stephen Till) for advice. We also thank Ms Melissa Tung for secretarial assistance.
No conflicts of interests were declared by authors.
1. Wang J, Sampson HA. Food anaphylaxis. Clin Exp Allergy 2007;37:651-60. CrossRef
2. Leung TF, Yung E, Wong YS, Lam CW, Wong GW. Parent-reported adverse food reactions in Hong Kong Chinese pre-schoolers: epidemiology, clinical spectrum and risk factors. Pediatr Allergy Immunol 2009;20:339-46. CrossRef
3. Ho MH, Lee SL, Wong WH, Ip P, Lau YL. Prevalence of self-reported food allergy in Hong Kong children and teens—a population survey. Asian Pac J Allergy Immunol 2012;30:275-84.
4. Sicherer SH, Noone SA, Muñoz-Furlong A. The impact of childhood food allergy on quality of life. Ann Allergy Asthma Immunol 2001;87:461-4. CrossRef
5. Li XM, Zhang TF, Huang CK, et al. Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 2001;108:639-46. CrossRef
6. Srivastava KD, Kattan JD, Zou ZM, et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 2005;115:171-8. CrossRef
7. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. Allergy 2009;64:1218-20. CrossRef
8. Hofmann AM, Scurlock AM, Jones SM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009;124:286-91. CrossRef
9. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009;124:292-300, 300.e1-97.
10. Blumchen K, Ulbricht H, Staden U, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010;126:83-91. CrossRef
11. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011;41:1273-81. CrossRef
12. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011;127:654-60. CrossRef
13. Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011;127:640-6. CrossRef
14. Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013;131:119-27.e1-7.
15. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348:986-93. CrossRef
16. Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011;127:1309-10. CrossRef
17. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93. CrossRef
18. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:1966-73. CrossRef
19. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45.
20. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-54. CrossRef
21. Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014;383:1297-304. CrossRef
22. Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007;120:688-95. CrossRef
23. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 2011;127:1622-4. CrossRef
24. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high risk peanut-allergic patients. J Allergy Clin Immunol 2013;132:1368-74. CrossRef
25. Lopes de Oliveira LC, Aderhold M, Brill M, et al. The value of specific IgE to peanut and its component Ara h 2 in the diagnosis of peanut allergy. J Allergy Clin Immunol Pract 2013;1:394-8. CrossRef
26. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005;303:81-91. CrossRef